Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600E |
Therapy | Panitumumab |
Indication/Tumor Type | colorectal cancer |
Response Type | resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E | colorectal cancer | resistant | Panitumumab | Clinical Study - Meta-analysis | Actionable | In a meta-analysis, the addition of Erbitux (cetuximab) or Vectibix (panitumumab) to standard of care treatment with chemotherapy did not result in improved progression-free survival (HR=0.88; 95% CI, 0.67-1.14; p=0.33), overall survival (HR=0.91; 95% CI, 0.62-1.34; p=0.63), or objective response rate (relative risk=1.31; 95% CI, 0.83-2.08; p=0.25) in patients with advanced colorectal cancer harboring BRAF V600E (PMID: 25673558). | 25673558 |
BRAF V600E | colorectal cancer | resistant | Panitumumab | Clinical Study | Actionable | In a retrospective analysis, metastatic colorectal cancer patients harboring BRAF V600E demonstrated shorter progression-free survival (p=0.0107) and overall survival (p<0.0001) compared to patients with wild-type BRAF following Vectibix (panitumumab) or Erbitux (cetuximab) therapy with or without chemotherapy, and in a preclinical study, colorectal cancer cell lines harboring BRAF V600E were resistant to Vectibix (panitumumab) in culture (PMID: 19001320). | 19001320 |
BRAF V600E | colorectal cancer | resistant | Panitumumab | Guideline | Actionable | Vectibix (panitumumab), as a monotherapy, is not indicated for use in metastatic colorectal cancer patients with BRAF V600E (PMID: 36307056; ESMO.org). | 36307056 detail... |
PubMed Id | Reference Title | Details |
---|---|---|
ESMO Clinical Practice Guidelines | Full reference... | |
(36307056) | Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. | Full reference... |
(25673558) | Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. | Full reference... |
(19001320) | Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. | Full reference... |